PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company is headquartered in Princeton, New Jersey and currently employs 54 full-time employees. The company went IPO on 2020-09-25. The firm is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. The company is deploying its precision oncology platform to target p53 mutations and other p53-related cancers. Its lead product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. In addition to its rezatapopt program, it is focused on developing a pipeline of product candidates targeting other p53 mutations or p53-related targets. These programs have been developed using its precision oncology platform.